Signals Inbox·August 25, 2026·Consumer Health

Is Oura really worth $16B today?

Yes, Oura can plausibly be worth $16B today, but the valuation works only if its near-$2B revenue trajectory, profitability and recurring membership economics hold up as it moves beyond smart rings.

Q1What exactly is Oura's $16B valuation today?

Oura’s latest completed private valuation is about $11 billion; the $16 billion figure is the price Bloomberg says Oura and some of its shareholders are now seeking in a U.S. IPO.

Bloomberg reported this week that Oura could raise as much as $3 billion in an offering valuing the smart-ring company above $16 billion. Existing shareholders are expected to sell a significant amount of stock as part of the deal. Oura had already confidentially filed for a U.S. IPO in May 2026.

The jump looks large because Oura was valued at $5.2 billion in its Series D in December 2024, then roughly $11 billion after raising more than $900 million in a Fidelity-led Series E in October 2025. ICONIQ, Whale Rock and Atreides also participated. A $16 billion IPO would add another 45% in less than a year and put Oura at more than three times its late-2024 valuation.

There is one counterpoint worth keeping in view. Bloomberg reported in January 2026 that Oura was considering a tender offer allowing existing investors to sell shares at roughly a 25% discount to the Series E price. That reported transaction was never a new primary funding round, so it did not reset Oura's official valuation. Still, it shows that the $11 billion headline price was not necessarily the price at which every shareholder could find liquidity a few months later.

Q2How much revenue does Oura actually make now?

Oura is already a billion-dollar revenue company, and CEO Tom Hale has said 2026 sales could come close to $2 billion.

Oura reported more than $500 million of revenue in 2024 after more than doubling sales. Research firm Sacra estimates that the company then reached about $1 billion in 2025, matching the target Oura had publicly given investors. Hale subsequently told CNBC that 2026 would be "north" of the company's earlier $1.5 billion forecast and could come close to $2 billion.

We should separate those numbers by confidence. The $500 million figure is historical company-reported revenue. Sacra's roughly $1 billion estimate for 2025 lines up with Oura's own guidance and with Hale's later comments about the year. The near-$2 billion figure is still a management projection rather than an audited result.

Even the conservative version gives Oura unusual scale for a wearable startup. A business that was around $220 million in revenue when Hale took over in 2022, according to his recent Business of Fashion interview, has grown several times over in only a few years.

Q3Has Oura's valuation risen faster than the business?

Oura's headline valuation has exploded, but so far its revenue has kept surprisingly close to the same pace.

At the end of 2024, Oura was valued at $5.2 billion while annual sales were around $500 million. The Series E pushed the valuation to about $11 billion as 2025 revenue headed toward $1 billion. The proposed IPO would move the valuation above $16 billion while management is aiming for substantially more than $1.5 billion of 2026 sales.

That pattern is more reassuring than a valuation chart by itself. From the Series D to the potential IPO, Oura's valuation would rise a little over threefold. If Hale gets close to his current 2026 sales target, revenue over roughly the same period would rise close to fourfold.

The odd piece in the middle is the reported discounted tender offer mentioned above. Primary investors were willing to fund Oura at $11 billion, while some secondary liquidity was later discussed at a lower price. The IPO will give us a much cleaner test because public investors will decide what Oura is worth with their own money.

Oura valuation and revenue progression

Q4What sales multiple are investors being asked to pay for Oura?

Oura at $16 billion looks expensive on last year's revenue and much more reasonable on the sales level Tom Hale says the company can reach now.

Using roughly $1 billion of 2025 revenue gives a 16x sales multiple. Oura's earlier official forecast of more than $1.5 billion for 2026 brings that below 10.7x. Hale's later CNBC projection of sales potentially approaching $2 billion brings it down to around 8x.

As we saw above, Oura has already carried a roughly 10–11x sales multiple through its last two major private valuation marks. Investors therefore do not need to assume another big expansion in the multiple to reach $16 billion. They need to believe the revenue forecast.

That is a much cleaner bet. If Oura comes in near $2 billion, an 8x multiple for a profitable company still growing this quickly is defensible. If revenue lands much closer to $1.5 billion and growth slows sharply after that, paying more than 10x becomes harder to justify.

Q5Is Oura expensive next to Garmin, Dexcom and Life360?

Yes, Oura currently deserves a premium to public wearable and health-tech companies, although a $16 billion price asks investors to believe that its much faster growth will continue.

Using current market caps and trailing revenue from StockAnalysis, Garmin trades around 7.3x sales, Dexcom around 7.0x and Life360 around 6.3x. Their growth rates are very different: Garmin's trailing revenue is up about 13.5%, Dexcom's about 15.5%, while Life360 is growing around 34%.

Oura has recently been growing on another level. Sacra estimates 2025 sales doubled, and Hale's current 2026 target implies another year of exceptionally fast expansion. Paying more for that growth makes sense.

The size of the premium is where things get interesting. At $1.5 billion of revenue, Oura would trade about 45% above Garmin's sales multiple, more than 50% above Dexcom's and almost 70% above Life360's. Near $2 billion, Oura's 8x multiple would sit only modestly above Garmin and Dexcom despite substantially faster growth.

Public investors will also see something they could not get from Oura's private rounds: audited margins, cash flow and a daily market price. Those numbers may end up moving the valuation more than another quarter of ring sales.

Oura versus public wearable and health-tech benchmarks

Q6Does Whoop make Oura's $16B valuation look reasonable?

Yes, Whoop is probably the best private-market argument for why a $16 billion Oura valuation is plausible.

The Financial Times reported that Whoop recently raised $575 million at a $10.1 billion valuation. Whoop had about 2.5 million users and an annual revenue run rate of roughly $800 million, implying a valuation of about 12.6x revenue.

That is richer than Oura would be at the conservative end of its current sales guidance. Whoop arguably deserves some extra credit because its model is more subscription-heavy: customers essentially pay for membership and receive the hardware as part of the service. Oura still gets most of its revenue from selling physical rings.

Oura has the scale advantage. Its paid membership base is around twice Whoop's reported user base, it dominates its own hardware category, and the company has said it has been profitable for several years. If investors recently accepted more than 12x revenue for Whoop, paying roughly 8–11x for Oura falls well inside the range private investors are already using for premium health wearables.

Q7Is Oura still growing unusually fast today?

Yes, Oura is still showing the kind of growth that can support a premium valuation, and the user numbers are almost as impressive as the revenue numbers.

In June 2024, Oura had sold about 2.5 million rings in its entire history. By September 2025, cumulative sales had passed 5.5 million. Roughly three million rings were therefore added in around 15 months, more than the company had sold during all the years before that milestone.

Paid membership has moved even faster. Oura said in May 2026 that it was on pace to pass five million paying members, more than four times the level two years earlier. The company also says 80% of members renew after their first year and 80% open the app at least five days a week.

Oura keeps adding distribution while those numbers rise. Its products were already available in more than 4,600 retail locations when it filed for an IPO, up from roughly 4,000 stores reported during the Series E period. The latest Oura Ring 5 also arrived this year with a 40% smaller design and a new software layer focused more heavily on predictive health.

That combination gives us more confidence than revenue growth alone. Oura is selling more devices, converting those devices into paid memberships and still getting members to use the product regularly after the initial novelty has worn off.

Q8Does Oura have enough recurring revenue to deserve a premium valuation?

Oura has built a serious recurring-revenue business, although the company still looks much more like hardware plus subscription than pure software.

Sacra estimates that roughly 80% of Oura's 2025 revenue came from hardware and around 20% from subscriptions. CEO Tom Hale gave essentially the same 20% subscription figure during the Series E period.

The subscription base has since become much larger. Oura currently charges $5.99 per month or $69.99 per year in the U.S. At five million paying members, the U.S. annual price would equate to roughly $350 million of annualized membership billings. Actual revenue will differ because Oura has regional prices, monthly plans and included trial periods, but the calculation shows the scale of the recurring layer.

Retention makes those subscribers more valuable. Oura says more than 80% renew after year one. The company also says 47% of new users hear about Oura through word of mouth, which suggests that at least part of its growth is arriving without the acquisition economics we normally associate with heavily advertised consumer hardware.

The multiple should reflect both sides of the business. Oura deserves more than a normal gadget-company multiple because millions of users keep paying after purchasing the device. A full software multiple would still be difficult to defend while ring sales account for most revenue.

Q9Is Oura actually profitable?

Yes, Oura says it has been profitable for several years, which makes its rapid growth much more valuable than the same growth funded by large operating losses.

Tom Hale told Fierce Healthcare in late 2024 that Oura was profitable. During an NYSE interview after the Series E, he went further and said the company had been profitable for "a couple of years" and was still expanding profitability.

Oura also entered its current IPO process with plenty of financing options. Alongside more than $900 million of Series E equity, the company arranged a $250 million revolving credit facility with JPMorgan, Goldman Sachs, Bank of America, Barclays, Citi and Wells Fargo. That does not prove strong free cash flow, but it shows Oura has access to conventional institutional financing as well as venture capital.

The missing numbers are now more interesting than the profitability claim itself. We still need Oura's operating margin, hardware gross margin, subscription gross margin and free cash flow from the public filing. Those figures will tell us whether Oura's profitability is merely positive or genuinely strong enough to deserve an 8–11x sales valuation.

Q10Is Oura still winning the smart-ring market?

Yes, Oura currently dominates smart rings by a huge margin, even after Samsung and several startups entered the category.

Omdia estimated that Oura held 74% of global smart-ring shipments in the first half of 2025. Samsung and Ultrahuman were each around 9%, while RingConn had roughly 5%. IDC data later cited by TechCrunch showed Oura reaching around 85% of the U.S. market during 2025.

We should be careful with that 85% figure because Oura benefited from legal restrictions on Ultrahuman imports in the U.S. Some of the latest share gain came while a major competitor had one hand tied behind its back.

The longer-term numbers still leave little doubt about who leads. Samsung entered with the scale of the world's largest smartphone maker and has yet to come close to Oura in rings. Ultrahuman has rebuilt its U.S. offering. RingConn remains active. Oura has faced all three while keeping a share that would be extraordinary in almost any consumer-electronics category.

That gives Oura room to spend on software, research and distribution from a much larger installed base than its direct ring competitors. It also creates a tougher growth problem: taking another ten points of market share becomes mathematically difficult when you already own most of the market.

Q11Is the smart-ring market big enough to support a $16B Oura?

The smart-ring market alone probably cannot carry a $16 billion Oura for long, so the valuation assumes that Oura keeps moving into the much larger health and wellness market.

IDC estimated that global smart-ring shipments jumped about 51% in 2025, reaching roughly 4.4 million units. It expects around 4.9 million in 2026, which would mean growth slowing to about 13%.

That slowdown deserves attention. Oura has recently grown far faster than 13%, partly because smart rings were moving from niche to mainstream and partly because Oura kept taking share. Repeating that formula becomes harder when the company already controls most of the category.

The next phase therefore has to come from several places at once: international expansion, more paid services per member, healthcare distribution, new health use cases and a bigger share of consumer wellness spending. The ring can remain the core product while the economics around each ring get broader.

Oura has already started moving in that direction. Health plans can distribute rings to members, employers can deploy them through Oura's enterprise platform, professional sports organizations are integrating the data into performance workflows, and Oura is adding metabolic health, women's health and clinical-history features inside the app.

A $16 billion valuation becomes much easier to understand if smart rings are Oura's entry point into continuous health monitoring rather than the full size of the opportunity.

Q12Can Samsung and Ultrahuman actually catch Oura?

Samsung and Ultrahuman can absolutely take customers from Oura, but catching Oura now requires beating a large installed base, strong retention and a patent portfolio that has already caused real problems for competitors.

Samsung has enormous distribution and can integrate Galaxy Ring with phones, watches and Android services. Ultrahuman has returned to the U.S. with Ring Pro and offers a different proposition around subscriptions. Competition is clearly getting tougher.

Oura has also shown that its intellectual property has teeth. A U.S. International Trade Commission ruling led to restrictions on Ultrahuman imports. RingConn later settled its dispute with Oura and agreed to pay royalties under a multi-year patent license. OMATE has signed a licensing agreement as well.

The fight with Samsung is broader and messier. Samsung has successfully challenged parts of Oura's patent portfolio, while Oura has also won important decisions. Most recently, the U.S. Patent Trial and Appeal Board rejected Samsung's attempt to invalidate Oura's patent covering a wearable computing device in the shape of a ring. Samsung has appealed.

Oura's protection therefore goes beyond having the best-known brand. A competitor needs good sensors, comfortable hardware, reliable algorithms, enough software to keep customers engaged, retail distribution and room to operate around Oura's IP. Samsung can afford that fight. Smaller entrants have a much harder path.

Q13Is Oura becoming more than a ring company?

Yes, Oura is currently building a broader health-data business around the ring, and several recent moves make that strategy look more concrete than it did a year ago.

Dexcom invested $75 million in Oura and connected glucose data with Oura's sleep, stress and activity information. Eli Lilly then made an equity investment in Oura this year as the company moved further into metabolic health. Oura says more than 100,000 members have already logged GLP-1 use in its app, and its new GLP-1 Insights product connects medication use with biometric trends.

Women's health has developed into another major branch of the product. Oura introduced pregnancy and perimenopause tools, built integrations with companies such as Natural Cycles, Midi Health and Progyny, and recently launched its first proprietary AI model specifically for women's health.

The technology roadmap is widening too. Oura acquired gesture-recognition startup Doublepoint, launched Oura Ring 5 with software designed to connect clinical history with continuous biometrics, and recently reorganized part of its technology leadership around AI and software engineering. The company says its ecosystem now includes more than 1,200 health, wellness and commercial partners.

The pattern is becoming fairly clear. Sleep brought people into Oura, recovery and women's health widened daily use, and metabolic health, AI guidance and healthcare partnerships are giving Oura more ways to make money from the same member over time.

Q14How much revenue would make Oura's $16B valuation look normal?

Oura needs roughly $2 billion of annual revenue to trade at 8x sales and about $2.7 billion to fall near the 6x level where some strong public consumer-health businesses trade today.

The 8x threshold is particularly relevant because Hale has already said Oura could come close to $2 billion this year. Reaching that level would put the proposed IPO much closer to normal premium public-market territory.

A 6x multiple would demand substantially more growth. At $16 billion, Oura would need about $2.67 billion of revenue. That is not a distant number if current growth persists, although public investors will want evidence rather than another management forecast.

Revenue required to support a $16B valuation

Q15What could make Oura look cheap at $16B?

Oura could grow into a $16 billion valuation surprisingly quickly if the current revenue target lands and growth remains strong for even one more year.

Suppose Oura reaches roughly $2 billion of sales and then grows 35% the following year, a major slowdown from its recent pace. Revenue would reach about $2.7 billion. With the valuation unchanged at $16 billion, the sales multiple would fall to roughly 5.9x.

That would put Oura around or below several public comparables on revenue despite still having faster growth. We would also be looking at a profitable business with millions of paying members, high first-year renewal, dominant market share and a growing healthcare business.

Recent product activity gives the scenario some credibility. Oura has released Ring 5, pushed deeper into AI health guidance, added GLP-1 features, expanded its sports footprint through Team USA, U.S. Soccer and the USTA, and brought Eli Lilly onto its shareholder list. Those moves give Oura more potential growth engines than simply selling another generation of rings to existing wellness enthusiasts.

If Oura can keep growing without giving up margins, today's apparently rich IPO price could look ordinary quite quickly.

Q16What could make Oura's $16B valuation fall apart?

Oura's biggest valuation risk is a sharp growth slowdown while hardware still makes up most of the business.

The smart-ring market gives us a reason to take that possibility seriously. IDC expects category unit growth to slow dramatically after last year's surge. Oura also has less market share left to capture, while Samsung, Ultrahuman and other wearable companies keep improving their products.

The revenue mix adds another vulnerability. Sacra's roughly 80% hardware estimate means Oura still depends heavily on people buying or replacing physical devices. Five million paying members create a valuable recurring base, but the economics are very different from a software company where nearly every additional dollar of revenue comes from subscriptions.

There is also a small but interesting valuation warning in Oura's own private-market history. Earlier this year, Bloomberg reported a proposed tender offer around 25% below the $11 billion Series E price. Now Bloomberg says existing shareholders may sell a significant amount of stock in the IPO. Neither fact proves that insiders think Oura is overvalued, but together they remind us that shareholder liquidity is part of this IPO story too.

A disappointing public filing could do more damage than any new smart ring. If Oura reveals modest gross margins, heavy marketing costs, weak free cash flow or slower current growth than Hale's earlier projection suggested, investors will have little reason to give the company a double-digit sales multiple.

Q17Is Oura really worth $16B today?

Our answer today is aggressive but plausible: $16 billion is a defensible valuation for Oura, although the company now needs its financial results to catch up with the story very quickly.

The public-market comparison gives us the clearest boundary. Oura is expensive beside Garmin, Dexcom and Life360 at the conservative end of its revenue outlook. The premium shrinks dramatically if sales come close to Hale's higher target. Whoop provides further support because private investors recently valued a smaller wearable platform at an even richer revenue multiple.

Oura also has several advantages we would actually pay extra for. It dominates smart rings, has around five million paid members, keeps more than 80% of members after the first year, says it is profitable, owns IP that competitors have already had to license or fight in court, and is finding new ways to use its health data beyond sleep tracking.

The weak point is just as clear. Most revenue still comes from hardware, and Oura cannot keep taking smart-ring share forever when it already owns most of the category. The next few billion dollars of company value have to come from recurring revenue, healthcare, international growth and higher spending per member.

At something close to $1.5 billion of annual sales, we would find $16 billion stretched. Near $2 billion, it looks reasonable for a company growing this fast. If Oura can then keep growing even 30–35% for another year while staying profitable, the multiple drops into public-company territory remarkably quickly.

So yes, Oura can be worth $16 billion today. We would not call it cheap, and the valuation leaves little room for a sudden slowdown. But the revenue growth, Whoop comparison, membership economics, profitability and current market leadership give the price enough support that calling it a bubble would ignore too much of what Oura has actually built.